TG Therapeutics, Inc. beat EPS estimates 38% of the time across 16 reported quarters (6 beats, 10 misses), averaging -15.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.05 | not reported | not reported | Q2 FY26 call · transcript |
| Q1 FY26 | $0.23 | $0.17 | -26.1% | Miss | |
| Q4 FY25 | $0.35 | $0.14 | -60.0% | Miss | Q4 FY25 call · transcript |
| Q3 FY25 | not reported | $2.43 | not reported | not reported | |
| Q2 FY25 | $0.32 | $0.17 | -46.9% | Miss | Q2 FY25 call · transcript |
| Q1 FY25 | not reported | $0.03 | not reported | not reported | |
| Q4 FY24 | $0.08 | $0.15 | +87.5% | Beat | |
| Q3 FY24 | $0.04 | $0.02 | -50.0% | Miss | |
| Q2 FY24 | not reported | $0.04 | not reported | not reported | |
| Q1 FY24 | $-0.03 | $-0.07 | -133.3% | Miss | |
| Q4 FY23 | $-0.12 | $-0.09 | +25.0% | Beat | |
| Q3 FY23 | not reported | $0.73 | not reported | not reported |
Back to TGTX overview · TGTX holders · TGTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.